Piramal Pharma to Acquire Remaining 26% Stake in Yapan Bio, Boosting Ownership to Full Control
Final acquisition terms and effective transfer date of shares are yet to be finalized following Board committee approval
Piramal Pharma Limited has approved exercising its call option to acquire the remaining 26% equity stake in its subsidiary, Yapan Bio Private Limited. The acquisition will make Yapan a wholly owned subsidiary, with final terms and effective date pending. Yapan specializes in vaccine and biologics manufacturing services.
Piramal Pharma Limited
Acquisition / Amalgamation / Merger / Demerger
Piramal Pharma Limited’s Board committee has approved exercising its call option to acquire the remaining 26% equity stake in its subsidiary Yapan Bio Private Limited, aiming to increase its ownership from 74% to 100%.
The acquisition will make Yapan Bio a wholly owned subsidiary of Piramal Pharma Limited.
Yapan Bio Private Limited operates as a contract development and manufacturing organization (CDMO) providing process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.
Post-approval, the company is engaged in discussions with Yapan’s existing shareholders to finalize the acquisition consideration and effective date for share transfer.
The final terms and completion of the transaction will be disclosed as per SEBI Listing Regulations.
The transaction consolidates Piramal Pharma's control over Yapan Bio, strengthening its presence in vaccine and biologics manufacturing services.
Highlights
- Piramal Pharma currently holds 74% equity in Yapan Bio.
- The company plans to acquire the remaining 26% stake via a call option.
- Yapan Bio specializes in vaccine and biologics process development and Phase I/II GMP manufacturing.
- Final transaction terms, including consideration and transfer date, are still being finalized.
- Completion disclosures will be made following execution of definitive documentation.
Key Data Snapshot
What happened
- Piramal Pharma’s Board committee approved exercising its call option to acquire the remaining 26% equity stake in Yapan Bio Private Limited.
- This acquisition will increase Piramal Pharma's ownership in Yapan Bio from 74% to 100%.
- Yapan Bio will become a wholly owned subsidiary upon completion of the transaction.
Key details
- Final terms including acquisition consideration and effective date of share transfer are still being negotiated.
- Disclosures as per SEBI regulations will follow upon completion of the transaction.
- Piramal Pharma is currently engaged in discussions with existing Yapan Bio shareholders to finalize transaction details.
Background and context
- Yapan Bio Private Limited is a Contract Development and Manufacturing Organization (CDMO).
- Specializes in process development, characterization, and Phase I/II GMP manufacturing services for vaccines and biologics.
- The acquisition aligns with Piramal Pharma’s strategic consolidation of its subsidiary.
Highlights
- Piramal Pharma currently holds 74% equity in Yapan Bio.
- The company plans to acquire the remaining 26% stake via a call option.
- Yapan Bio specializes in vaccine and biologics process development and Phase I/II GMP manufacturing.
- Final transaction terms, including consideration and transfer date, are still being finalized.
- Completion disclosures will be made following execution of definitive documentation.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30, 2026
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
FIH Mauritius Investments Ltd Acquires 3.24% Additional Stake in IIFL Capital Services, Becoming Promoter
FIH Mauritius Investments Ltd acquired 1,20,58,525 equity shares representing 3.24% stake in IIFL Capital Services Limited through an open offer completed on November 18, 2026. This acquisition boosted their total shareholding to 41.28%, making them the promoter of IIFL Capital Services as of November 19, 2026.
Read Full StoryICICI Prudential AMC Secures SEBI Approval to Acquire PMS Business from ICICI Securities
ICICI Prudential Asset Management Company Limited announced receipt of SEBI's approval to acquire the Portfolio Management Services business from ICICI Securities Limited, allowing the progression of the slump sale transaction agreed earlier in 2026.
Read Full Story3B BlackBio Dx's Coris BioConcept Acquires Bilex SRL to Own Manufacturing Facility, Generating €140,000 Annual Savings
Coris BioConcept SRL, a subsidiary of 3B BlackBio Dx Limited, acquired 100% ownership of Bilex SRL, the entity that owns the land and building of Coris's manufacturing plant and office in Gembloux, Belgium, for €274,817. This acquisition, completed on November 18, 2026, transitions Coris from tenant to owner, eliminating rental payments and generating annual savings.
Read Full Story